Skye Bioscience, Inc. (SKYE)
| Market Cap | n/a-87.6% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,683 |
| Open | n/a |
| Previous Close | 1.62 |
| Day's Range | 1.62 - 1.75 |
| 52-Week Range | 1.50 - 14.08 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SKYE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SKYE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SKYE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SKYE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SKYE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SKYE from public contracts
Source: USAspending.gov
SKYE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SKYE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score